TNF and rheumatoid arthritis: TNF-α inhibitors were the first bDMARDs approved by the US Food and Drug Administration for RA, introduced sequentially as follows: etanercept (1998), infliximab (1999), adalimumab (ADA) (2002), certolizumab pegol (2009), and golimumab (2009) [76].